Keyword: Ovid Therapeutics
Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.
Ovid CEO Jeremy Levin discussed what the company has learned about developing orphan drugs from its experience with Angelman syndrome.
Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.
CEOs weigh in on increasingly large biotech IPOs and an increase in companies going public at earlier stages.
After reporting mixed results earlier this year, Ovid has new trial data for its OV101 drug in Angelman syndrome that it says look a lot stronger.
Ovid Therapeutics has posted a batch of topline data out of its midstage STARS trial in Angelman syndrome as it seeks out a path to approval.
The pair will start three new trials in the third quarter, including a phase 2 pilot study in CDKL5 deficiency disorder and duplication 15q syndrome.
GeneTx will develop an antisense drug for Angelman syndrome, a genetic disorder that affects the nervous system.
Our panel discussed the meaning of good science and how different players can work together to leverage their respective strengths.
We kick off a new long form series assessing the life science industry from its leaders with ex-Teva chief Jeremy Levin.